@misc{Goldman-Mazur_Sarah_Clinical_2020,
 author={Goldman-Mazur, Sarah},
 address={Kraków},
 howpublished={online},
 year={2020},
 school={Rada Dyscypliny Nauki medyczne},
 language={pol; eng},
 abstract={This monography consists of the two publications concerning theprognostic impact of translocations involving MAF(musculoaponeurotic fibrosarcoma) genes, namely translocationst(14;16) and t(14;20) in newly diagnosed multiple myeloma patients.The aim of this retrospective study was to present the clinicalcharacteristics and survival outcomes on a large group of patients withthose translocations. 254 patients with MM diagnosed betweenOctober 2005 and January 2018, testing positively for t(14;20) ort(14;16) were identified from the medical records at 29 participatinginstitutions all over the world. For t(14;16) the median PFS was 24.9months and median OS was 49.0 months; for t(14;20) median PFSwas 16.6 months and median OS was 54.0 months. In conclusion, bothtranslocations seem to have a similar implication for prognosis inaddition to their similar mechanism. The t(14;20) should beconsidered as an adverse factor of equal prognostic implication as thet(14;16) abnormality in the staging systems. Myeloma patients withMAF translocations who received double ASCT display superior OSin this retrospective dataset.},
 title={Clinical and cytogenetic prognostic factors in multiple myeloma},
 type={Praca doktorska},
 keywords={t(14;16), translocation, myeloma, t(14;20), MAF},
}